Key clinical point: Erenumab is effective in managing patients with treatment-resistant chronic migraine in a tertiary care setting without causing any serious adverse effects.

Major finding: At 3 and 6 months, erenumab significantly reduced the median monthly migraine days (MMD; −4 and −9 days, respectively; P < .001), with the MMD 50% responder rate at 3 months being 36%. No serious adverse events were observed.

Study details: This was a prospective study including 92 patients aged >18 years with chronic migraine and ≥3 prior migraine preventive treatment failures who received monthly 70 mg erenumab for 3 months.

Disclosures: The authors did not report any source of funding or conflict of interests.

Source: Khalil M et al. Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real-world evidence. Eur J Neurol. 2022 (Apr 21). Doi: 10.1111/ene.15364

Key clinical point: Erenumab is effective in managing patients with treatment-resistant chronic migraine in a tertiary care setting without causing any serious adverse effects.

Major finding: At 3 and 6 months, erenumab significantly reduced the median monthly migraine days (MMD; −4 and −9 days, respectively; P < .001), with the MMD 50% responder rate at 3 months being 36%. No serious adverse events were observed.

Study details: This was a prospective study including 92 patients aged >18 years with chronic migraine and ≥3 prior migraine preventive treatment failures who received monthly 70 mg erenumab for 3 months.

Disclosures: The authors did not report any source of funding or conflict of interests.

Source: Khalil M et al. Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real-world evidence. Eur J Neurol. 2022 (Apr 21). Doi: 10.1111/ene.15364

Key clinical point: Erenumab is effective in managing patients with treatment-resistant chronic migraine in a tertiary care setting without causing any serious adverse effects.

Major finding: At 3 and 6 months, erenumab significantly reduced the median monthly migraine days (MMD; −4 and −9 days, respectively; P < .001), with the MMD 50% responder rate at 3 months being 36%. No serious adverse events were observed.

Study details: This was a prospective study including 92 patients aged >18 years with chronic migraine and ≥3 prior migraine preventive treatment failures who received monthly 70 mg erenumab for 3 months.

Disclosures: The authors did not report any source of funding or conflict of interests.

Source: Khalil M et al. Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real-world evidence. Eur J Neurol. 2022 (Apr 21). Doi: 10.1111/ene.15364

Key clinical point: Fremanezumab treatment leads to clinically meaningful improvement in patients with migraine for up to 6 months, regardless of the dosing regimen or number of prior migraine preventive treatment failures.

Major finding: At 6 months, mean percentage reductions from baseline in monthly migraine days, monthly headache days, Migraine Disability Assessment score, and 6-item Headache Impact Test score were 72.4% (−9.2 days), 70.0% (−9.8 days), 63.1% (−18.1 days), and 27.0% (−16.2 days), respectively. Subgroups formed according to the dosing schedule and number of prior migraine preventive treatment failures showed similar improvements.

Study details: This was a retrospective, online physician chart review study that included data from 421 clinicians and 1003 patients with migraine who had initiated fremanezumab treatment at ≥18 years of age and received ≥1 fremanezumab dose.

Disclosures: The study was sponsored by Teva Pharmaceuticals. Some authors declared being current or former employees of Teva. The other authors are employees of an organization funded by Teva.

Source: Driessen MT et al. Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study. J Headache Pain. 2022;23:47 (Apr 11). Doi: 10.1186/s10194-022-01411-1

Key clinical point: Fremanezumab treatment leads to clinically meaningful improvement in patients with migraine for up to 6 months, regardless of the dosing regimen or number of prior migraine preventive treatment failures.

Major finding: At 6 months, mean percentage reductions from baseline in monthly migraine days, monthly headache days, Migraine Disability Assessment score, and 6-item Headache Impact Test score were 72.4% (−9.2 days), 70.0% (−9.8 days), 63.1% (−18.1 days), and 27.0% (−16.2 days), respectively. Subgroups formed according to the dosing schedule and number of prior migraine preventive treatment failures showed similar improvements.

Study details: This was a retrospective, online physician chart review study that included data from 421 clinicians and 1003 patients with migraine who had initiated fremanezumab treatment at ≥18 years of age and received ≥1 fremanezumab dose.

Disclosures: The study was sponsored by Teva Pharmaceuticals. Some authors declared being current or former employees of Teva. The other authors are employees of an organization funded by Teva.

Source: Driessen MT et al. Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study. J Headache Pain. 2022;23:47 (Apr 11). Doi: 10.1186/s10194-022-01411-1

Key clinical point: Fremanezumab treatment leads to clinically meaningful improvement in patients with migraine for up to 6 months, regardless of the dosing regimen or number of prior migraine preventive treatment failures.

Major finding: At 6 months, mean percentage reductions from baseline in monthly migraine days, monthly headache days, Migraine Disability Assessment score, and 6-item Headache Impact Test score were 72.4% (−9.2 days), 70.0% (−9.8 days), 63.1% (−18.1 days), and 27.0% (−16.2 days), respectively. Subgroups formed according to the dosing schedule and number of prior migraine preventive treatment failures showed similar improvements.

Study details: This was a retrospective, online physician chart review study that included data from 421 clinicians and 1003 patients with migraine who had initiated fremanezumab treatment at ≥18 years of age and received ≥1 fremanezumab dose.

Disclosures: The study was sponsored by Teva Pharmaceuticals. Some authors declared being current or former employees of Teva. The other authors are employees of an organization funded by Teva.

Source: Driessen MT et al. Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study. J Headache Pain. 2022;23:47 (Apr 11). Doi: 10.1186/s10194-022-01411-1

Key clinical point: Gastrectomy significantly improves survival in older patients with resectable gastric cancer. Renal disease is an independent risk predictor for poorer survival in patients who undergo surgery.

Major finding: In propensity-matched analysis (n = 44), the 3-year overall survival (OS) was significantly longer in the radical surgery vs conservative therapy group (59.4% vs 15.9%, P < .01). No surgery was independently associated with worse OS in the entire cohort (hazard ratio [HR] 3.70; P = .0001). In the surgery group, renal disease was an independent risk factor for poorer OS (HR 2.51; P < .05).

Study details: This was a retrospective observational study of patients aged ≥75 years with clinically resectable primary gastric cancer who underwent radical surgery (n = 115) or received conservative therapy (n = 33).

Disclosures: No funding source was identified for this study. The authors declared no competing interests.

Source: Ito S et al. Survival benefits of gastrectomy compared to conservative observation for older patients with resectable gastric cancer: A propensity score matched analysis. Langenbecks Arch Surg. 2022 (Apr 29). Doi: 10.1007/s00423-022-02511-x

Key clinical point: Gastrectomy significantly improves survival in older patients with resectable gastric cancer. Renal disease is an independent risk predictor for poorer survival in patients who undergo surgery.

Major finding: In propensity-matched analysis (n = 44), the 3-year overall survival (OS) was significantly longer in the radical surgery vs conservative therapy group (59.4% vs 15.9%, P < .01). No surgery was independently associated with worse OS in the entire cohort (hazard ratio [HR] 3.70; P = .0001). In the surgery group, renal disease was an independent risk factor for poorer OS (HR 2.51; P < .05).

Study details: This was a retrospective observational study of patients aged ≥75 years with clinically resectable primary gastric cancer who underwent radical surgery (n = 115) or received conservative therapy (n = 33).

Disclosures: No funding source was identified for this study. The authors declared no competing interests.

Source: Ito S et al. Survival benefits of gastrectomy compared to conservative observation for older patients with resectable gastric cancer: A propensity score matched analysis. Langenbecks Arch Surg. 2022 (Apr 29). Doi: 10.1007/s00423-022-02511-x

Key clinical point: Gastrectomy significantly improves survival in older patients with resectable gastric cancer. Renal disease is an independent risk predictor for poorer survival in patients who undergo surgery.

Major finding: In propensity-matched analysis (n = 44), the 3-year overall survival (OS) was significantly longer in the radical surgery vs conservative therapy group (59.4% vs 15.9%, P < .01). No surgery was independently associated with worse OS in the entire cohort (hazard ratio [HR] 3.70; P = .0001). In the surgery group, renal disease was an independent risk factor for poorer OS (HR 2.51; P < .05).

Study details: This was a retrospective observational study of patients aged ≥75 years with clinically resectable primary gastric cancer who underwent radical surgery (n = 115) or received conservative therapy (n = 33).

Disclosures: No funding source was identified for this study. The authors declared no competing interests.

Source: Ito S et al. Survival benefits of gastrectomy compared to conservative observation for older patients with resectable gastric cancer: A propensity score matched analysis. Langenbecks Arch Surg. 2022 (Apr 29). Doi: 10.1007/s00423-022-02511-x

Key clinical point: Apatinib plus programmed cell death protein 1 (PD-1) inhibitors show promising response and acceptable tolerance in previously treated real-world patients with advanced gastric cancer.

Major finding: The median follow-up duration was 7.3 months. The objective response rate was 20.5% and disease control rate was 69.2%. The median progression-free survival (PFS) was 3.9 months (95% CI 2.74-5.06), and the median overall survival (OS) was 7.8 (95% CI 4.82-10.78) months. The most common adverse events were fatigue (61.5%), nausea and vomiting (56.4%), diarrhea (48.7%), hypertension (46.2%), hand-foot syndrome (38.5%), and rash (28.2%).

Study details: This was a real-world study of 39 previously treated patients with advanced gastric cancer who received apatinib plus PD-1 blockade treatment between August 2018 and October 2021.

Disclosures: This study was supported by the Natural Science Foundation of Henan Province, China. The authors declared no conflicts of interest.

Source: Li LH et al. Feasibility and tolerance of apatinib plus PD-1 Inhibitors for previously treated;advanced gastric cancer: A real-world exploratory study. Dis Markers. 2022; 4322404 (Apr 29). Doi: 10.1155/2022/4322404

Key clinical point: Apatinib plus programmed cell death protein 1 (PD-1) inhibitors show promising response and acceptable tolerance in previously treated real-world patients with advanced gastric cancer.

Major finding: The median follow-up duration was 7.3 months. The objective response rate was 20.5% and disease control rate was 69.2%. The median progression-free survival (PFS) was 3.9 months (95% CI 2.74-5.06), and the median overall survival (OS) was 7.8 (95% CI 4.82-10.78) months. The most common adverse events were fatigue (61.5%), nausea and vomiting (56.4%), diarrhea (48.7%), hypertension (46.2%), hand-foot syndrome (38.5%), and rash (28.2%).

Study details: This was a real-world study of 39 previously treated patients with advanced gastric cancer who received apatinib plus PD-1 blockade treatment between August 2018 and October 2021.

Disclosures: This study was supported by the Natural Science Foundation of Henan Province, China. The authors declared no conflicts of interest.

Source: Li LH et al. Feasibility and tolerance of apatinib plus PD-1 Inhibitors for previously treated;advanced gastric cancer: A real-world exploratory study. Dis Markers. 2022; 4322404 (Apr 29). Doi: 10.1155/2022/4322404

Key clinical point: Apatinib plus programmed cell death protein 1 (PD-1) inhibitors show promising response and acceptable tolerance in previously treated real-world patients with advanced gastric cancer.

Major finding: The median follow-up duration was 7.3 months. The objective response rate was 20.5% and disease control rate was 69.2%. The median progression-free survival (PFS) was 3.9 months (95% CI 2.74-5.06), and the median overall survival (OS) was 7.8 (95% CI 4.82-10.78) months. The most common adverse events were fatigue (61.5%), nausea and vomiting (56.4%), diarrhea (48.7%), hypertension (46.2%), hand-foot syndrome (38.5%), and rash (28.2%).

Study details: This was a real-world study of 39 previously treated patients with advanced gastric cancer who received apatinib plus PD-1 blockade treatment between August 2018 and October 2021.

Disclosures: This study was supported by the Natural Science Foundation of Henan Province, China. The authors declared no conflicts of interest.

Source: Li LH et al. Feasibility and tolerance of apatinib plus PD-1 Inhibitors for previously treated;advanced gastric cancer: A real-world exploratory study. Dis Markers. 2022; 4322404 (Apr 29). Doi: 10.1155/2022/4322404

Key clinical point: Firstline trastuzumab-based chemotherapy shows poorer survival in patients with rescued vs initially human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer.

Major finding: The median follow-up duration was 47.6 months. Rescued HER2-positive patients had a higher rate of immunohistochemistry (IHC) score 2+/in situ hybridization-positive (ISH+; 37.0%) tumors. The median progression-free survival (PFS; 5.7 vs 8.4 months; P = .034) and overall survival (OS; 11.3 vs 16.7 months; P = .02) were significantly shorter in IHC 2+/ISH+ vs IHC 3+ patients. Rescued vs initially HER2-positive patients had worse PFS (5.4 vs 7.8 months; P = .017) and OS (10.4 vs 16.3 months; P = .036).

Study details: A retrospective analysis of 153 patients with HER2-positive advanced gastric cancer who received first-line trastuzumab-based chemotherapy.

Disclosures: No funding source was identified for this work. The authors received consulting fees and honoraria. JH Cheon was the founder and shareholder of Novomics.

Source: Bang K et al. Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab. Gastric Cancer. 2022 (May 7). Doi: 10.1007/s10120-022-01298-6

Key clinical point: Firstline trastuzumab-based chemotherapy shows poorer survival in patients with rescued vs initially human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer.

Major finding: The median follow-up duration was 47.6 months. Rescued HER2-positive patients had a higher rate of immunohistochemistry (IHC) score 2+/in situ hybridization-positive (ISH+; 37.0%) tumors. The median progression-free survival (PFS; 5.7 vs 8.4 months; P = .034) and overall survival (OS; 11.3 vs 16.7 months; P = .02) were significantly shorter in IHC 2+/ISH+ vs IHC 3+ patients. Rescued vs initially HER2-positive patients had worse PFS (5.4 vs 7.8 months; P = .017) and OS (10.4 vs 16.3 months; P = .036).

Study details: A retrospective analysis of 153 patients with HER2-positive advanced gastric cancer who received first-line trastuzumab-based chemotherapy.

Disclosures: No funding source was identified for this work. The authors received consulting fees and honoraria. JH Cheon was the founder and shareholder of Novomics.

Source: Bang K et al. Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab. Gastric Cancer. 2022 (May 7). Doi: 10.1007/s10120-022-01298-6

Key clinical point: Firstline trastuzumab-based chemotherapy shows poorer survival in patients with rescued vs initially human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer.

Major finding: The median follow-up duration was 47.6 months. Rescued HER2-positive patients had a higher rate of immunohistochemistry (IHC) score 2+/in situ hybridization-positive (ISH+; 37.0%) tumors. The median progression-free survival (PFS; 5.7 vs 8.4 months; P = .034) and overall survival (OS; 11.3 vs 16.7 months; P = .02) were significantly shorter in IHC 2+/ISH+ vs IHC 3+ patients. Rescued vs initially HER2-positive patients had worse PFS (5.4 vs 7.8 months; P = .017) and OS (10.4 vs 16.3 months; P = .036).

Study details: A retrospective analysis of 153 patients with HER2-positive advanced gastric cancer who received first-line trastuzumab-based chemotherapy.

Disclosures: No funding source was identified for this work. The authors received consulting fees and honoraria. JH Cheon was the founder and shareholder of Novomics.

Source: Bang K et al. Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab. Gastric Cancer. 2022 (May 7). Doi: 10.1007/s10120-022-01298-6

Key clinical point: Carbon nanoparticle suspension lymphography-guided distal gastrectomy improves postoperative lymph node detection rate in patients with gastric cancer undergoing gastrectomy.

Major finding: A higher mean number of lymph nodes were detected with vs without carbon nanoparticle suspension injection (CNSI; 59.6 vs 30.0; P < .001). A higher number of lymph nodes were detected in black- vs nonblack-stained stations (9.2 vs 3.5 lymph nodes per station; P < .001).

Study details: This was a retrospective cohort study including 156 propensity score-matched patients with clinical T1-T4 gastric cancer who underwent laparoscopic or robotic distal gastrectomy with or without (conventional group) CNSI between May 2019 and December 2020.

Disclosures: This study was supported by the University Research Project of Hebei Province and the Medical Research Project of Hebei Province, China. The authors declared no conflicts of interest.

Source: Tian Y et al. Assessment of carbon nanoparticle suspension lymphography–guided distal gastrectomy for gastric cancer. JAMA Netw Open. 2022;5(4):e227739 (Apr 18). Doi: 10.1001/jamanetworkopen.2022.7739

Key clinical point: Carbon nanoparticle suspension lymphography-guided distal gastrectomy improves postoperative lymph node detection rate in patients with gastric cancer undergoing gastrectomy.

Major finding: A higher mean number of lymph nodes were detected with vs without carbon nanoparticle suspension injection (CNSI; 59.6 vs 30.0; P < .001). A higher number of lymph nodes were detected in black- vs nonblack-stained stations (9.2 vs 3.5 lymph nodes per station; P < .001).

Study details: This was a retrospective cohort study including 156 propensity score-matched patients with clinical T1-T4 gastric cancer who underwent laparoscopic or robotic distal gastrectomy with or without (conventional group) CNSI between May 2019 and December 2020.

Disclosures: This study was supported by the University Research Project of Hebei Province and the Medical Research Project of Hebei Province, China. The authors declared no conflicts of interest.

Source: Tian Y et al. Assessment of carbon nanoparticle suspension lymphography–guided distal gastrectomy for gastric cancer. JAMA Netw Open. 2022;5(4):e227739 (Apr 18). Doi: 10.1001/jamanetworkopen.2022.7739

Key clinical point: Carbon nanoparticle suspension lymphography-guided distal gastrectomy improves postoperative lymph node detection rate in patients with gastric cancer undergoing gastrectomy.

Major finding: A higher mean number of lymph nodes were detected with vs without carbon nanoparticle suspension injection (CNSI; 59.6 vs 30.0; P < .001). A higher number of lymph nodes were detected in black- vs nonblack-stained stations (9.2 vs 3.5 lymph nodes per station; P < .001).

Study details: This was a retrospective cohort study including 156 propensity score-matched patients with clinical T1-T4 gastric cancer who underwent laparoscopic or robotic distal gastrectomy with or without (conventional group) CNSI between May 2019 and December 2020.

Disclosures: This study was supported by the University Research Project of Hebei Province and the Medical Research Project of Hebei Province, China. The authors declared no conflicts of interest.

Source: Tian Y et al. Assessment of carbon nanoparticle suspension lymphography–guided distal gastrectomy for gastric cancer. JAMA Netw Open. 2022;5(4):e227739 (Apr 18). Doi: 10.1001/jamanetworkopen.2022.7739

Key clinical point: Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) significantly decreased postoperative peritoneal recurrence and prolonged survival in patients with clinical T4 gastric cancer who underwent gastrectomy with lymphadenectomy.

Major finding: Prophylactic HIPEC vs no HIPEC significantly lowered the overall recurrence rate (34.3% vs 62.9%; P = .04) and postoperative peritoneal carcinomatosis (21.7% vs 57.1%; P = .03). HIPEC significantly improved the overall survival (OS) rate (71.4% vs 40.0%; P = .01). Patients in the HIPEC group had a significantly longer OS (adjusted hazard ratio [aHR] 0.37; P = .035) and disease-free survival (aHR 0.33; P = .017).

Study details: This was a retrospective study of 132 patients with clinical stage T4 gastric cancer who underwent gastrectomy plus D2 lymphadenectomy between 2014 and 2020. Thirty-five of the 132 patients received prophylactic HIPEC perioperatively.

Disclosures: No funding source was identified for this work. The authors declared no competing interests.

Source: Lee TY et al. Prophylactic hyperthermic intraperitoneal chemotherapy for patients with clinical T4 gastric cancer. Eur J Surg Oncol. 2022 (Apr 27). Doi: 10.1016/j.ejso.2022.04.018

Key clinical point: Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) significantly decreased postoperative peritoneal recurrence and prolonged survival in patients with clinical T4 gastric cancer who underwent gastrectomy with lymphadenectomy.

Major finding: Prophylactic HIPEC vs no HIPEC significantly lowered the overall recurrence rate (34.3% vs 62.9%; P = .04) and postoperative peritoneal carcinomatosis (21.7% vs 57.1%; P = .03). HIPEC significantly improved the overall survival (OS) rate (71.4% vs 40.0%; P = .01). Patients in the HIPEC group had a significantly longer OS (adjusted hazard ratio [aHR] 0.37; P = .035) and disease-free survival (aHR 0.33; P = .017).

Study details: This was a retrospective study of 132 patients with clinical stage T4 gastric cancer who underwent gastrectomy plus D2 lymphadenectomy between 2014 and 2020. Thirty-five of the 132 patients received prophylactic HIPEC perioperatively.

Disclosures: No funding source was identified for this work. The authors declared no competing interests.

Source: Lee TY et al. Prophylactic hyperthermic intraperitoneal chemotherapy for patients with clinical T4 gastric cancer. Eur J Surg Oncol. 2022 (Apr 27). Doi: 10.1016/j.ejso.2022.04.018

Key clinical point: Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) significantly decreased postoperative peritoneal recurrence and prolonged survival in patients with clinical T4 gastric cancer who underwent gastrectomy with lymphadenectomy.

Major finding: Prophylactic HIPEC vs no HIPEC significantly lowered the overall recurrence rate (34.3% vs 62.9%; P = .04) and postoperative peritoneal carcinomatosis (21.7% vs 57.1%; P = .03). HIPEC significantly improved the overall survival (OS) rate (71.4% vs 40.0%; P = .01). Patients in the HIPEC group had a significantly longer OS (adjusted hazard ratio [aHR] 0.37; P = .035) and disease-free survival (aHR 0.33; P = .017).

Study details: This was a retrospective study of 132 patients with clinical stage T4 gastric cancer who underwent gastrectomy plus D2 lymphadenectomy between 2014 and 2020. Thirty-five of the 132 patients received prophylactic HIPEC perioperatively.

Disclosures: No funding source was identified for this work. The authors declared no competing interests.

Source: Lee TY et al. Prophylactic hyperthermic intraperitoneal chemotherapy for patients with clinical T4 gastric cancer. Eur J Surg Oncol. 2022 (Apr 27). Doi: 10.1016/j.ejso.2022.04.018

Key clinical point: The body composition variables were associated with major postoperative complications in patients with gastric cancer who received preoperative chemotherapy followed by gastrectomy.

Major finding: A high skeletal muscle (SM)-mass Z-score (difference in each patient’s standard deviation from the mean value) was associated with a lower risk for major postoperative complications (relative risk [RR] 0.47, P = .004). High visceral adipose tissue-radiation attenuation (VAT-RA; RR 2.82; P = .001) and subcutaneous adipose tissue-RA (SAT-RA; RR 1.95; P = .015) Z-scores were associated with an increased risk for major postoperative complications.

Study details: This was a side study of 112 patients with gastric cancer who received preoperative chemotherapy followed by gastrectomy in the LOGICA trial. The preoperative computed tomography scan was used to calculate the mass and RA for SM, VAT, and SAT.

Disclosures: This study was sponsored by the Netherlands Organization for Health Research and Development. The authors received consulting or advisory fees, travel or accommodations expenses, or grants outside this work.

Source: Tweed TTT et al. Body composition is a predictor for postoperative complications after gastrectomy for gastric cancer: A prospective side study of the LOGICA trial. J Gastrointest Surg. 2022 (Apr 29). Doi: 10.1007/s11605-022-05321-0

Key clinical point: The body composition variables were associated with major postoperative complications in patients with gastric cancer who received preoperative chemotherapy followed by gastrectomy.

Major finding: A high skeletal muscle (SM)-mass Z-score (difference in each patient’s standard deviation from the mean value) was associated with a lower risk for major postoperative complications (relative risk [RR] 0.47, P = .004). High visceral adipose tissue-radiation attenuation (VAT-RA; RR 2.82; P = .001) and subcutaneous adipose tissue-RA (SAT-RA; RR 1.95; P = .015) Z-scores were associated with an increased risk for major postoperative complications.

Study details: This was a side study of 112 patients with gastric cancer who received preoperative chemotherapy followed by gastrectomy in the LOGICA trial. The preoperative computed tomography scan was used to calculate the mass and RA for SM, VAT, and SAT.

Disclosures: This study was sponsored by the Netherlands Organization for Health Research and Development. The authors received consulting or advisory fees, travel or accommodations expenses, or grants outside this work.

Source: Tweed TTT et al. Body composition is a predictor for postoperative complications after gastrectomy for gastric cancer: A prospective side study of the LOGICA trial. J Gastrointest Surg. 2022 (Apr 29). Doi: 10.1007/s11605-022-05321-0

Key clinical point: The body composition variables were associated with major postoperative complications in patients with gastric cancer who received preoperative chemotherapy followed by gastrectomy.

Major finding: A high skeletal muscle (SM)-mass Z-score (difference in each patient’s standard deviation from the mean value) was associated with a lower risk for major postoperative complications (relative risk [RR] 0.47, P = .004). High visceral adipose tissue-radiation attenuation (VAT-RA; RR 2.82; P = .001) and subcutaneous adipose tissue-RA (SAT-RA; RR 1.95; P = .015) Z-scores were associated with an increased risk for major postoperative complications.

Study details: This was a side study of 112 patients with gastric cancer who received preoperative chemotherapy followed by gastrectomy in the LOGICA trial. The preoperative computed tomography scan was used to calculate the mass and RA for SM, VAT, and SAT.

Disclosures: This study was sponsored by the Netherlands Organization for Health Research and Development. The authors received consulting or advisory fees, travel or accommodations expenses, or grants outside this work.

Source: Tweed TTT et al. Body composition is a predictor for postoperative complications after gastrectomy for gastric cancer: A prospective side study of the LOGICA trial. J Gastrointest Surg. 2022 (Apr 29). Doi: 10.1007/s11605-022-05321-0

Key clinical point: First-degree relatives of patients with gastric cancer show a high prevalence of preneoplastic lesions (PNL).

Major finding: The prevalence of PNL, atrophic gastritis, and intestinal metaplasia in first-degree relatives of gastric cancer patients were 86.4%, 82.7%, and 54.5%, respectively. The incidence of PNL was not significantly associated with sex (odds ratio [OR] 3.10; 95% confidence interval [CI] 1.00-9.64), age (OR 0.74; 95% CI, 0.26-2.14), and Helicobacter pylorii infection (OR 0.58; 95% CI 0.12-2.77). The advanced stages of Operative Link on Gastritis Assessment and Operative Link on Gastritis/Intestinal-Metaplasia Assessment were verified in 18.0% and 16.3% of the first-degree relatives, respectively.

Study details: This was a cross-sectional study including 110 first-degree relatives of patients with gastric cancer.

Disclosures: This study was partially supported by CONICYT, Chile. The authors declared no conflicts of interest.

Source: Sotelo S et al. Prevalence of gastric preneoplastic lesions in first-degree relatives of patients with gastric cancer: A cross-sectional study. J Gastrointest Cancer. 2022 (Apr 30). Doi: 10.1007/s12029-022-00827-x

Key clinical point: First-degree relatives of patients with gastric cancer show a high prevalence of preneoplastic lesions (PNL).

Major finding: The prevalence of PNL, atrophic gastritis, and intestinal metaplasia in first-degree relatives of gastric cancer patients were 86.4%, 82.7%, and 54.5%, respectively. The incidence of PNL was not significantly associated with sex (odds ratio [OR] 3.10; 95% confidence interval [CI] 1.00-9.64), age (OR 0.74; 95% CI, 0.26-2.14), and Helicobacter pylorii infection (OR 0.58; 95% CI 0.12-2.77). The advanced stages of Operative Link on Gastritis Assessment and Operative Link on Gastritis/Intestinal-Metaplasia Assessment were verified in 18.0% and 16.3% of the first-degree relatives, respectively.

Study details: This was a cross-sectional study including 110 first-degree relatives of patients with gastric cancer.

Disclosures: This study was partially supported by CONICYT, Chile. The authors declared no conflicts of interest.

Source: Sotelo S et al. Prevalence of gastric preneoplastic lesions in first-degree relatives of patients with gastric cancer: A cross-sectional study. J Gastrointest Cancer. 2022 (Apr 30). Doi: 10.1007/s12029-022-00827-x

Key clinical point: First-degree relatives of patients with gastric cancer show a high prevalence of preneoplastic lesions (PNL).

Major finding: The prevalence of PNL, atrophic gastritis, and intestinal metaplasia in first-degree relatives of gastric cancer patients were 86.4%, 82.7%, and 54.5%, respectively. The incidence of PNL was not significantly associated with sex (odds ratio [OR] 3.10; 95% confidence interval [CI] 1.00-9.64), age (OR 0.74; 95% CI, 0.26-2.14), and Helicobacter pylorii infection (OR 0.58; 95% CI 0.12-2.77). The advanced stages of Operative Link on Gastritis Assessment and Operative Link on Gastritis/Intestinal-Metaplasia Assessment were verified in 18.0% and 16.3% of the first-degree relatives, respectively.

Study details: This was a cross-sectional study including 110 first-degree relatives of patients with gastric cancer.

Disclosures: This study was partially supported by CONICYT, Chile. The authors declared no conflicts of interest.

Source: Sotelo S et al. Prevalence of gastric preneoplastic lesions in first-degree relatives of patients with gastric cancer: A cross-sectional study. J Gastrointest Cancer. 2022 (Apr 30). Doi: 10.1007/s12029-022-00827-x

Key clinical point: The oxaliplatin- vs cisplatin-based regimen does not show significant difference in survival benefits in elderly patients with advanced gastric cancer.

Major finding: The overall survival was not significantly different between the oxaliplatin and cisplatin groups (hazard ratio 1.13; P = .70). A significantly lower number of patients received granulocyte colony-stimulating factor in the oxaliplatin vs cisplatin group (2.3% vs 22.7%; P = .01).

Study details: This was a propensity score-matched analysis of 242 patients aged ≥70 years with advanced gastric cancer who received oxaliplatin- or cisplatin-based treatment regimen.

Disclosures: This study was supported by the Ministry of Education, Culture, Sports, Science, and Technology, Japan. The authors declared no competing interests.

Source: Chinen T et al. Oxaliplatin- versus cisplatin-based regimens for elderly individuals with advanced gastric cancer: a retrospective cohort study. BMC Cancer. 2022;22:460 (Apr 26). Doi: 10.1186/s12885-022-09581-6

Key clinical point: The oxaliplatin- vs cisplatin-based regimen does not show significant difference in survival benefits in elderly patients with advanced gastric cancer.

Major finding: The overall survival was not significantly different between the oxaliplatin and cisplatin groups (hazard ratio 1.13; P = .70). A significantly lower number of patients received granulocyte colony-stimulating factor in the oxaliplatin vs cisplatin group (2.3% vs 22.7%; P = .01).

Study details: This was a propensity score-matched analysis of 242 patients aged ≥70 years with advanced gastric cancer who received oxaliplatin- or cisplatin-based treatment regimen.

Disclosures: This study was supported by the Ministry of Education, Culture, Sports, Science, and Technology, Japan. The authors declared no competing interests.

Source: Chinen T et al. Oxaliplatin- versus cisplatin-based regimens for elderly individuals with advanced gastric cancer: a retrospective cohort study. BMC Cancer. 2022;22:460 (Apr 26). Doi: 10.1186/s12885-022-09581-6

Key clinical point: The oxaliplatin- vs cisplatin-based regimen does not show significant difference in survival benefits in elderly patients with advanced gastric cancer.

Major finding: The overall survival was not significantly different between the oxaliplatin and cisplatin groups (hazard ratio 1.13; P = .70). A significantly lower number of patients received granulocyte colony-stimulating factor in the oxaliplatin vs cisplatin group (2.3% vs 22.7%; P = .01).

Study details: This was a propensity score-matched analysis of 242 patients aged ≥70 years with advanced gastric cancer who received oxaliplatin- or cisplatin-based treatment regimen.

Disclosures: This study was supported by the Ministry of Education, Culture, Sports, Science, and Technology, Japan. The authors declared no competing interests.

Source: Chinen T et al. Oxaliplatin- versus cisplatin-based regimens for elderly individuals with advanced gastric cancer: a retrospective cohort study. BMC Cancer. 2022;22:460 (Apr 26). Doi: 10.1186/s12885-022-09581-6